Duramed Pharmaceuticals, Inc. v. Paddock Laboratories, Inc., No. 10-01419, 2011 BL 189841 (Fed. Cir. July 21, 2011) The U.S. Court of Appeals affirmed a district court's grant of summary judgment of noninfringement of an estrogen replacement drug patent, finding infringement under the doctrine of equivalents was barred by prosecution history estoppel. Moisture Barrier Coating Amendment Duramed Pharmaceuticals, Inc. ("Duramed") is the owner of U.S. Patent No. 5,908,638 (the '638 patent), relating to estrogen pharmaceutical compositions coated with a moisture barrier coating ("MBA") for use in hormone replacement therapies. During prosecution, Duramed overcame an obviousness rejection by amending claim 1 to limit the MBA to "ethylcellulose." Duramed markets its estrogen hormone replacement therapy product as CENESTIN. Paddock Laboratories, Inc. ("Paddock") filed an Abbreviated New Drug Application ("ANDA"), seeking FDA approval to market a generic version of CENESTIN. Paddock's proposed generic formulation, marketed as Opadry AMB, comprises a polyvinyl alcohol ("PVA") MBA instead of ethylcellulose. In response, Duramed brought suit in the U.S. District Court for the Southern District of New York against Paddock, alleging infringement of claims 1, 4, and 6-8 of the '638 patent under the doctrine of equivalents. Paddock moved for summary judgment of noninfringement, asserting that Duramed was barred by prosecution history estoppel from alleging that PVA met the ethylcellulose MBA limitation of the asserted claims. The district court granted Paddock's noninfringement summary judgment motion, finding that the amendment adding the ethylcellulose limitation was substantially related to patentability and narrowed the scope of the asserted claims, thus triggering the presumption of surrender for all equivalents under Festo Corp. v. Shoketsu Kinzoku Kogyo Kabushiki Co., 344 F.3d 1359 (Fed. Cir. 2003) (en banc). The district court also held that Duramed failed to rebut the Festo presumption, finding that use of PVA as a MBA in a pharmaceutical composition was foreseeable at the time of the amendment. Prosecution History Estoppel Bars Equivalence Infringement The Federal Circuit affirmed the noninfringement summary judgment, finding prosecution history estoppel barred Duramed from asserting infringement under the doctrine of equivalents. The court noted that since Duramed narrowed the scope of claim 1 in response to a prior art rejection, a presumption of prosecution history estoppel applied. Additionally, the Federal Circuit found that Duramed failed to rebut the presumption by showing that the alleged equivalent would have been unforeseeable at the time of the amendment. Rejecting Duramed's definition of the field of the invention restricting the suitability of PVA or Opadry AMB for use with conjugated estrogens, the Federal Circuit stated that when both original and issued claims begin "with the words '[a] pharmaceutical composition,' that language defines the field of the invention for purposes of determining foreseeability." Duramed at 7-8 (citing Schwarz Pharma, Inc. v. Paddock Labs., Inc., 504 F.3d 1371, 1377 (Fed. Cir. 2007)). Finding that an international patent application filed prior to the amendment pursuant to the Patent Cooperation Treaty ("PCT") disclosed formulations of PVA MBAs, including Opadry AMB, the Federal Circuit concluded that such PVA MBAs were known in the field of the invention, and, thus foreseeable. The Federal Circuit clarified that "even if the PCT disclosure indicates that PVA is less than ideal in some pharmaceutical uses as an MBC, it is still disclosed to be useful as such, and that renders it foreseeable for purposes of prosecution history estoppel. Foreseeability does not require flawless perfection to create an estoppel." Id. at 9. The court held that Duramed failed to rebut the presumption of prosecution history estoppel by showing that PVA MBCs would have been unforeseeable at the time of its narrowing amendment. Accordingly, the Federal Circuit affirmed the district court's grant of summary judgment of noninfringement.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)